Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Uniqure NV

QURE ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$48.62

▲ +3.31%

Market Cap $3.37B · Vol 354.26K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.37B

Mid Cap

Div Yield

N/A

EPS Growth

-9.95%

YoY

RSI (14)

80.42

Momentum

Beta

0.94

vs Market

52W High

$71.24

31.75% below

52W Low

$8.74

456.29% above

Volume

354.26K

Avg 408.44K

P/B

7.50

Price-to-book

ROE

N/A

Return on equity

Free Float

95.66%

Public shares

Shariah Compliance8 STANDARDS

✗ Uniqure NV (QURE) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does QURE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.74%

+17.10%

+75.21%

+137.17%

YTD

+103.18%

+208.11%

+445.68%

+66.74%

Financials & Valuation

TTM · Annual

Total Revenue	$16.10M
Net Income	$-198,971,000.00
Revenue Growth (YoY)	+11.00%
Gross Margin	89.53%
Operating Margin	-1,110.71%
Net Profit Margin	-1,236.00%
ROE	N/A
ROA · ROIC	-27.99% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	85.48
P/B	7.50
P/FCF	N/A
EPS Growth	-9.95%
Outstanding Shares	69.37M

Technical Indicators

50-Day SMA	$40.59
200-Day SMA	$27.74
RSI (14)	80.42
Beta	0.94
52-Week High	$71.24
52-Week Low	$8.74

Volume Today	354.26K
Avg Daily Volume (30D)	408.44K
Relative Volume	0.87x
Volatility (10D)	30.61
Volatility (30D)	47.96
Free Float	95.66%

Analyst Consensus

BUY

Current Price $48.62

Mean Target $68.00

52W Low$8.74 52W High$71.24

Current

Target

$8.74 $71.24

Current Analyst target

+39.86% upside potential · 12 analysts

Identifiers

ExchangeNasdaq

FIGIBBG005SSJYG4

ISINNL0010696654

CountryNetherlands

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.